LOS ANGELES, May 08, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ:GDRX) common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period").
If you suffered a loss on your GoodRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/goodrx-holdings-inc-1/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance. In its shareholder letter, the Company stated that "a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs." The Company expects "the grocer issue . . . could have an estimated revenue ...
GDRX)>Full story available on Benzinga.com